Contents lists available at ScienceDirect





journal homepage: www.elsevier.com/locate/envint

Comparative mammalian hazards of neonicotinoid insecticides among exposure durations



Zhen Wang^a, Bryan W. Brooks^{a,b}, Eddy Y. Zeng^a, Jing You^{a,*}

^a School of Environment, Guangdong Key Laboratory of Environmental Pollution and Health, Jinan University, Guangzhou, China ^b Department of Environmental Science, Institute of Biomedical Studies, Baylor University, Waco, TX, USA

ARTICLE INFO

ABSTRACT

Handling Editor: Frederic Coulon Keywords: Neonicotinoids Chemical toxicity distribution Threshold of toxicological concern Uncertainty factor Probabilistic health hazard assessment Neonicotinoid insecticides have become one of the most widely used insecticides over the past two decades. Recent studies have shown considerable risk of neonicotinoids to beneficial insects, however, their health risks to mammals are still under debate. Limited empirical mammalian toxicity information for neonicotinoids inherently presents challenges to environmental health practitioners performing health hazard and risk assessment. Therefore, we first compiled and examined publicly available hazard data for neonicotinoids, and knowledge gaps on mammals were identified. Probabilistic hazard assessment using chemical toxicity distributions (CTDs) was subsequently conducted, and initial thresholds of toxicological concern were derived for rat, dog, mouse, and rabbit under comparative experimental scenarios. Using the rat model, for example, oral 5% threshold concentrations (TC5s) of 0.11 (0.02, 0.36) and 0.23 (0.001, 3.2) mg/kg bw/day were estimated using chronic developmental and reproductive no observed adverse effect levels (NOAELs), respectively, while acute TC5 of 0.71 (0.25, 1.6) mg/kg bw/day was identified using neurological NOAELs. Comparatively, dermal and inhalational TC5s were estimated as 1583 (1172, 1777) and 451 (294, 615) mg/kg bw/day (equivalent to 486 (322, 622) mg/m³), respectively, using acute median lethal doses. Uncertainty factors (UFs) were also estimated using both CTD comparisons and individual UF probability distribution approaches to test whether rodent oral toxicity information or default 10-fold UF approach can provide sufficient protection for mammals. These initially identified UFs were generally smaller than default values (e.g., 10) employed by regulatory stakeholders, yet larger UFs were occasionally noted. Our findings appear particularly useful for environmental health practitioners when conducting screening-level risk assessment for neonicotinoids, and provide an example for health hazard assessment of pesticides with limited toxicity information.

1. Introduction

Neonicotinoid insecticides have been extensively used for agricultural, veterinary, and residential practices globally since their introduction in the 1990s because of their systemic characteristics and high efficacy for insect control (Simon-Delso et al., 2015). Recent studies demonstrate that neonicotinoids are ubiquitous in the environment, resulting from their ever-growing use, high mobility, and relatively long environmental half-lives in water and soil. Their broad occurrence has presented urgent risks to biodiversity and integrity of beneficial organisms and populations (Goulson, 2013; Hladik et al., 2018). In addition to environmental media, including source waters for potable uses, neonicotinoids have also been frequently detected in food products, and hence directly or indirectly increase the probability for mammalian species or human exposures to neonicotinoids. For instance, the U.S. Department of Agriculture (USDA, 2014, 2016) found neonicotinoids in 12 of 19 fruits and vegetables sampled, with 11 of them containing multiple neonicotinoids, and the levels of thiamethoxam exceeded the maximum residue limit in summer squash. Other evidence of contamination of neonicotinoids and their metabolites was also demonstrated in drinking water (Seccia et al., 2005; Klarich et al., 2017), vegetables, fruits (Xie et al., 2011), bovine milk (Seccia et al., 2008), and honey (Mitchell et al., 2017).

Neonicotinoids are considered to be less potent to mammalian species in comparison with legacy insecticide classes (e.g., organochlorines, organophosphates, and carbamates) (Tomizawa and Casida, 2005; Jeschke et al., 2013); however, studies showed that exposure to neonicotinoids pose potential risks to mammalian species or humans (Han et al., 2018; Zhang et al., 2018). Neonicotinoids can adversely affect mammalian nicotinic acetylcholine receptors, leading to

https://doi.org/10.1016/j.envint.2019.01.040

Received 14 December 2018; Received in revised form 15 January 2019; Accepted 15 January 2019 Available online 26 January 2019 0160-4120/ © 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

^{*} Corresponding author.

E-mail address: youjing@jnu.edu.cn (J. You).

Constructional Cost Constructional model Control Contro Contro Contro </th <th></th>																
Memorphic 1 Due UP Display Display <th>Chemical</th> <th>CAS</th> <th>Country/ agency</th> <th>Acceptab) mg/kg bv</th> <th>le daily inta v/day)</th> <th>ke (ADI;</th> <th>Acute refe bw/day)</th> <th>rence dose (ARfL</th> <th>); mg/kg</th> <th>Chronic refe bw/day)</th> <th>erence dose (CRI</th> <th>fD; mg/kg</th> <th>Acceptable systemic (A</th> <th>operator expc OEL; mg/kg b</th> <th>sure level - w/day)</th> <th>Source (reference)</th>	Chemical	CAS	Country/ agency	Acceptab) mg/kg bv	le daily inta v/day)	ke (ADI;	Acute refe bw/day)	rence dose (ARfL); mg/kg	Chronic refe bw/day)	erence dose (CRI	fD; mg/kg	Acceptable systemic (A	operator expc OEL; mg/kg b	sure level - w/day)	Source (reference)
Matriality Matriality Matriality Matriality Matriality Matriality Matri Matriality Matriality Matriality Matriality Matriality Matrialit				ADI	Dose	UF	ARfD	Dose	UF	CRfD	Dose	UF	AOEL	Dose	UF	I
Normania	Acetamiprid	135410-20-7	US EPA	NA	L C	007	0.1	10	100	0.07	7.1	100	NA	L	007	(US EPA, 2002)
Attribut			EU FAO/WHO	620.0 0.07	c.2	100	620.0 0.1	c.7	100	NA			620.0 NA	c.7	100	(EF5A, 2013; EC, 2017) (JMPR, 2017)
			Australia	0.1	6	100	NA			NA			NA			(Commonwealth of Australia 2017)
Cubination 21080-951 anomany BUN Control Contro Control Control			Health	0.008	2.5	300	0.008	2.5	300	NA			NA			(Health Canada, 2010)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Clothianidin	210880-92-5	us epa	NA			0.025	25	1000	0.0098	9.8	1000	NA			(US EPA. 2003b)
$ \ \ \ \ \ \ \ \ \ \ \ \ \ $			EU	0.097		100	0.1	10	100	NA			0.1	10	100	(EC, 2005)
			FA0/WH0	0.1			0.6			NA			NA			(JMPR, 2012, 2014, 2017)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Australia	0.05	9.7	100	NA			NA			NA			(Commonwealth of
			Health	NR			NR			NR			NR			Austrana, 2017) (Health Canada, 2017a)
Dimentional 15522-70-0 NA NA <td></td> <td></td> <td>Canada</td> <td></td>			Canada													
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Dinotefuran	165252-70-0	US EPA	NA			1.25	125	100	0.02	20 (LOAEL)	1000	NA			(US EPA, 2004)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			EU	0.22	22	100	1.75	175	100	NA			0.22		100	(EC, 2014)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			FAO/WHO	0.2	00	100	1			NA			NA			(JMPR, 2012)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Australia	0.2	77	100	NA			NA			NA			(Commonwealth of Australia, 2017)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Imidacloprid	138261-41-3	US EPA	NA			0.14	42 (LOAEL)	300	0.057	5.7	100	NA			(US EPA, 2005)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			EU	0.06			0.08			NA			0.08			(EC, 2015)
Australia 0.06 6 100 NA NA Commonscality NA Thiadoprid Hath 0.06 5.7 100 0.08 8 100 NA NA NA Thiadoprid 111988-499 Usmala 0.01 3.1 300 0.04 1.2 300 NA NA Australia 0.01 1.2 100 NA NA NA NA Australia 0.01 1.2 300 0.04 1.2 300 NA NA Inianethoxan 153719-34 U 0.04 1.2 300 NA NA NA Inianethoxan 153719-34 U 0.04 1.2 300 NA NA NA Inianethoxan 153719-34 U 0.04 1.2 300 NA NA NA Inianethoxan 153719-34 U 0.02 2.6 100 NA NA NA Inianethoxan			FAO/WHO	0.06			0.4			NA			NA			(JMPR, 2017)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Australia	0.06	9	100	NA			NA			NA			(Commonwealth of
			Health	0.06	5.7	100	0.08	α	100	NA			NA			Austrania, 2017) (Health Canada 2016)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Canada	0		2	2000)	0							
	Thiacloprid	111988-49-9	US EPA	NA			0.01	3.1	300	0.004	1.2	300	NA			(US EPA, 2003a)
Australia0.011.2100NANANANANAHealth0.041.2300NA <td< td=""><td></td><td></td><td>EU</td><td>0.01</td><td></td><td></td><td>0.03</td><td></td><td></td><td>NA</td><td></td><td></td><td>0.02</td><td></td><td></td><td>(EC, 2004)</td></td<>			EU	0.01			0.03			NA			0.02			(EC, 2004)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			Australia	0.01	1.2	100	NA			NA			NA			(Commonwealth of
			Health	0.004	1 2	300	0.01	3.1	300	NA			NA			Australia, 2017) (Health Canada 2007)
Thiamethoxam 13719-23-4 US EPA NA 1 100 100 0.006 0.6 100 NA (US EPA, 2001) EU 0.026 2.6 100 0.5 50 100 NA NA (US EPA, 2001) FAO/WHO 0.08 2.6 100 0.5 50 100 NA NA (NBR, 2014) Australia 0.02 2 100 NA NA NA NA NA Australia 0.02 2 100 NA NA NA NA NA NA Imidaclothiz 15843-36-5 NA NA NA NA NA Imidaclothiz 158843-36-5 NA NA NA NA NA Imidaclothiz 1588447-8 NA NA NA NA Nithizine 58842-20-9 NA NA NA NA Nithizine 58842-20-9 NA NA NA NA			Canada		1	200	10.0		200	1741						(1000 contaction) 2000 D
EU 0.026 2.6 100 0.5 50 100 NA 0.08 8 100 (JWFR, 2014) FAO/WHO 0.08 0.0 0.03 1 NA NA NA 0.08 8 100 (GMmouvalh Australia 0.02 2 100 NA NA NA NA NA NA Australia 0.02 2 100 NA	Thiamethoxam	153719-23-4	US EPA	NA			1	100	100	0.006	0.6	100	NA			(US EPA, 2001)
FAO/WHO 0.08 1 NA NA NA MAR, 2014) Australia 0.02 2 100 NA NA NA (Gommonwalth Australia, 2017) Health NR NR NR NR NR (Gommonwalth Australia, 2017) Imidaclothiz 105843-36-5 NA NR NR NR Imidaclothiz 105843-36-5 NA NR NR Nitenpyram 150824-47-8 NA NA Nithiazine 58842-20-9 NA NA Nithiazine 58842-20-9 NA NA Nithiazine 58842-20-9 NA NA Nationogding 94899+16-9 NA NA			EU	0.026	2.6	100	0.5	50	100	NA			0.08	80	100	(EC, 2006)
Australia 0.02 2 100 NA NA (Commonshib) Australia 0.02 2 100 NA (Commonshib) (Commonshib) Health NR NR NR NR (Health Canada, Commonship) (Health Canada, Commonship) Imidaclothiz 105843-36-5 NA NR NR (Health Canada, Commonship) Nitenpyram 15082447-8 NA NA NA NA Nithiazine 58842-20-9 NA NA NA NA Paichongding 94894-16-9 NA NA NA NA			FA0/WHO	0.08			1			NA			NA			(JMPR, 2014)
Health NR NR Austanta, 2010 Imidaclothiz 105843-36-5 NA NR (Health Canada, 100) Imidaclothiz 105843-36-5 NA NA NA Nitenpyram 150824-47-8 NA NA NA Nithiazine 58842-20-9 NA NA NA Paichongding 94894-16-9 NA NA NA			Australia	0.02	2	100	NA			NA			NA			(Commonwealth of
Imidaclothiz 105843-36-5 NA NA NA Nitenpyram 150824-47-8 NA NA Nithiazine 58842-20-9 NA NA Paichongding 948994-16-9 NA NA			Health	NR			NR			NR			NR			Ausuana, 2017) (Health Canada 2017h)
Imidaclothiz 105843-36-5 NA NA NA Nitenpyram 15082447-8 NA NA NA Nithiazine 58842-20-9 NA NA NA Paichongding 94899416-9 NA NA NA			Canada													
Nitenpyram 15082447-8 NA NA NA Nithiazine 58842-20-9 NA NA NA Paichongding 94899416-9 NA NA NA	Imidaclothiz	105843-36-5		NA			NA			NA			NA			
Nithiazine 58842-20-9 NA NA NA Paichongding 948994-16-9 NA NA NA NA	Nitenpyram	150824-47-8		NA			NA			NA			NA			
Parchongding 948994-16-9 NA NA NA	Nithiazine	58842-20-9		NA			NA			NA			NA			
	Paichongding	948994-16-9		NA			NA			NA			NA			

factor (UF) of 100 was used accounting for 10-fold of intra-species variances; Composite UF (one > 100) was used accounting for 100-fold intra-species variances, and additional uncertainties. The corresponding mammalian toxicity studies of NOAELs/LOAELs are summarized in Table S1. NA indicates that data is not available, and NR indicates that data is not reported. Notes: US EPA: the United States Environmental Protection Agency; EU: the European Union; FAO/WHO: the Food and Agriculture Organization of the United Nations/World Health Organization; NA indicates data was not available; NR indicates no human risks identified for clothianidin and thiamethoxam by Health Canada (2017a, b); Dose refers to NOAEL used for a given HLV, unless stated otherwise (LOAEL); Default uncertainty

neurobehavioral deficits and increased expression of glial fibrillary acidic protein in the motor cortex and hippocampus (Abou-Donia et al., 2008; Li et al., 2011; Kimura-Kuroda et al., 2012). These receptors are important for nervous system functions, including memory, cognition and behavior development (Kimura-Kuroda et al., 2012; Chen et al., 2014). Detrimental effects of neonicotinoids to mammalian species included developmental (e.g., decreased body weight and reduced food consumption and water intake), reproductive (e.g., decreased sperm production and function (motility), and delayed sexual maturation), and neurological responses (e.g., decreased motor and locomotor activities), and skin and eye irritation, and even tumor (thiacloprid) (US EPA, 2002, 2003a, b, 2004).

Recognizing potential risks of neonicotinoids to mammals or humans, a number of regulatory human limit values (HLVs), such as acceptable daily intakes (ADIs), acute/chronic reference dose (ARfD/ CRfD), and acceptable operator exposure level (AOEL; systemic) have been established for neonicotinoid around the world (Table 1). Due to paucity of human epidemiological data, most of current HLVs for neonicotinoids were derived from the existing mammalian toxicity information (Table S1) and adjusted by appropriate uncertainty factors (UFs) for conservatism. Mammal chronic no observed adverse effect level (NOAEL) or lowest observed adverse effect level (LOAEL) values commonly served as point of departure (PoD), and a default 100-fold UF approach was used accounting for inter- (10-fold) and intra-species (10-fold) variances when establishing HLVs (US EPA, 2002; EFSA, 2013; Commonwealth of Australia, 2017). Additional composition UF accounting for extrapolations of LOAEL-to-NOAEL (UF_{L-N}) or subchronic-to-chronic (UF $_{\rm S-C}$), adequacy of database, or modifying factor was also adopted upon less than ideal data for a chemical (US EPA, 2003a, 2005; Health Canada, 2010). Take acetamiprid as an example, ARfD and CRfD of 0.1 and 0.07 mg/kg bw/day were recommended by the U. S. Environmental Protection Agency (US EPA, 2002) based on rodent acute neurotoxicity (male LOAEL: 30 mg/kg/day) and chronic/ oncogenicity studies (male and female LOAEL: 17.5 mg/kg/day), respectively. More stringently, the European Union (EFSA, 2013; EC, 2017) refined HLVs (ADI, ARfD, AOEL, and acute AOEL (AAOEL)) for acetamiprid to a value of 0.025 mg/kg bw/day when they applied a smaller NOAEL of 2.5 mg/kg bw/day (developmental neurotoxicity) as a PoD. Health Canada (2010) dropped the ADI and ARfD for acetamiprid to 0.008 mg/kg bw/day by dividing the NOAEL of 2.5 mg/ kg bw/day by a composite UF of 300 (additional 3-fold was refined as Pest Control Products Act factor).

Though commonly used in regulatory settings, whether default UF approach (e.g., 100-fold) can provide sufficient (or over- or under-) protection for humans when mammalian toxicity data of neonicotinoids are used as surrogates remains understudied. Whether rodent oral toxicity information can provide adequate protection for other mammal species under comparative experimental scenarios has not been robustly evaluated. A critical review is also warranted to examine all publicly available hazard data for mammalian species under comparative exposure scenarios, and to identify data gaps for future toxicity testing. Therefore, three primary objectives were targeted in the current study. First, we collated and examined publicly available acute median lethal dose (LD50) and developmental, reproductive and neurological NOAEL and LOAEL values of neonicotinoids under comparative experimental scenarios for different model species from previous sources for knowledge gaps identifications. Probabilistic hazard assessment (PHA) using chemical toxicity distribution (CTD) were subsequently conducted for particular endpoints (e.g., rat oral developmental chronic NOAEL), and threshold concentrations and corresponding 95% confidence intervals (95% CIs) were derived for identifying initial thresholds of toxicological concern (TTCs), based on existing information. Finally, both CTD comparisons and individual UF probability distribution approaches were used to identify UFs for neonicotinoids, including 1) extrapolations of LD50-to-NOAEL (e.g., acute-to-chronic ratios (ACRs)), exposure durations (e.g., subchronic-to-chronic), and LOAEL-

to-NOAEL within a model species, 2) species-to-species extrapolation (e.g., rat-to-mouse/rabbit), and 3) route-to-route extrapolation (e.g., oral-to-dermal/inhalation).

2. Methods

2.1. Data mining

In this review, ten currently used neonicotinoids were considered (see Table S2 for their physicochemical properties), and hazard data of nine neonicotinoids (except for paichongding) for common mammalian toxicology model species (rat, dog, mouse, and rabbit) under oral, dermal, and inhalation exposures were collected from publicly available databases and peer-reviewed publications. The databases include US EPA Office of Pesticide Programs (US EPA OPP), Pesticide Properties Database (PPDB), Toxicology Data Network (TOXNET), and California EPA Department of Pesticide Regulation (California EPA DPR). Toxicity endpoints included LD50s for lethality, and acute/subacute/subchronic/chronic NOAELs and LOAELs for developmental, reproductive, and neurological responses.

2.2. Chemical toxicity distributions (CTDs)

Probabilistic hazard assessments (PHA) using CTDs approach were conducted for each neonicotinoid using datasets we reviewed and compiled. Briefly, any outlier(s) detected by Grubbs' (Grubbs, 1969) or Tietjen-Moore (Tietjen and Moore, 1972) tests were excluded for each dataset. A geometric mean was used when there were multiple data for a chemical under a particular exposure scenario for a species. Only datasets contained a minimum of five data points (i.e., at least five neonicotinoids) were used for CTDs constructions. Normality of residuals for each dataset (log-transformed) was checked by the Shapiro-Francia test (Shapiro and Francia, 1972), and goodness of fit at the lower tail of each distribution was assessed by Anderson-Darling test (Anderson and Darling, 1954). Hazard data were then ranked in ascending order, and percentiles were assigned from the Weibull formula (Eq. (1)).

$$Percentile = i/(n+1) \times 100\%$$
(1)

where i is the rank of the datum in ascending order and n is the total number of data points. The CTDs were constructed and fitted by the log-normal regression model (SigmaPlot, version 13.0, San Jose, CA, USA).

Threshold concentration (TC) values and corresponding 95% CIs at 1^{st} , 5^{th} , 10^{th} , 50^{th} , 90^{th} , 95^{th} , and 99^{th} percentiles for each CTD were determined from the log-normal model by incorporating Monte Carlo simulation approach (resampled 5000 times) in the Statistical Analysis System package (SAS, version 9.4, Cary, NC, USA). For unit consistency (mg/kg bw/day), rat inhalation acute LD50 data expressed in mg/L were first transformed to mg/m³, and subsequently converted to mg/kg bw/day based on an allometric approach (Bide et al., 2000) (see Appendix A for data-transformation methodology). Rat inhalation acute LD50 CTDs using data with units of mg/m³ and mg/kg bw/day, respectively, were constructed for TCs and 95% CIs estimates.

2.3. Uncertainty factors (UFs)

In the present study, both CTD comparisons and individual UF probability distributions approaches were used to identify UFs for neonicotinoids within a model species (e.g., ACRs, UF_{S-C} , and UF_{L-N}), species-to-species, and route-to-route extrapolations under a particular experimental scenario following our previously reported methods (Wang et al., 2018). In brief, the UFs were first derived from pairwise TC ratios and 95% CIs from corresponding pairwise CTDs using all available data (in SAS as mentioned above). Concurrent meta-analyses were conducted using two corresponding datasets containing common (similar) chemicals to rectify potential influences caused by different

chemical compositions for both CTDs. The slope and/or intercept parameters of the pairwise log-normal fitted CTDs were also compared by one-way analysis of covariance (ANCOVA; SPSS, version 23, Chicago, IL, USA). To further compare differences between the two distributions quantitatively, TC5 ratio (95% CI) was applied for each comparison; if the 95% CI overlapped with unity, then the ratio was equal to 1 (i.e., both CTDs shared similar sensitivity) (Sokal and Rohlf, 1995). Second, UFs were calculated separately for all chemicals from the pairwise datasets containing common chemicals, and corresponding hazard data available to a similar species for a given endpoint. All calculated UFs were then ranked and assigned percentiles following the Weibull formula (Eq. 1) to construct a probability distribution, which was then fitted by the log-normal regression model. Afterwards, overall UFs and 95% CIs covering 90%, 95%, and 99% of concerned chemicals were determined for each distribution with an inverse prediction method. Whether a factor of 10 or 100 would be protective for various distributions of neonicotinoids was examined.

3. Results and discussion

3.1. Data availability and knowledge gaps

Availability of data varied significantly across the neonicotinoids of concern (Table S3). Hazard data for acetamiprid, clothianidin, dinotefuran, imidacloprid, thiacloprid, and thiamethoxam had high representativeness of various concerned toxicity endpoints, which accounted for > 50% of time for the endpoints of concern. They also dominated 20 generated CTDs (datasets with \geq 5 neonicotinoids) with 80%-95% of frequency. On the contrary, a few acute data were available for imidaclothiz (two acute LD50s), nitenpyram (five acute LD50s), and nithiazine (three acute LD50s, one rat oral developmental acute NOAEL, and one rat oral neurological acute NOAEL), and no hazard data were found for paichongding. In addition, hazard data for rats under oral exposure dominated the datasets among species and exposure routes of concern, respectively. This represented an important observation because oral exposure through pesticide residues in food represents an important exposure route for humans. The application of CTDs (as demonstrated below) was also largely dependent on the quantity of data. In this study, and consistent with previous practices (Dobbins et al., 2008, 2009; Berninger and Brooks, 2010; Williams et al., 2011; Berninger et al., 2011; Dreier et al., 2015; Wang et al., 2018), a dataset containing a minimum of five data points was considered to be suitable for CTD development, particularly considering data availability for neonicotinoids. Scarce and even no toxicity data for imidaclothiz, nitenpyram, nithiazine, and paichongding calls for additional data generation (toxicity testing) or read across from other neonicotinoids to fill data gaps during future hazard and risk assessments.

3.2. Chemical toxicity distributions (CTDs) and thresholds of toxicological concern (TTCs)

Among all datasets used to construct CTDs, no outlier(s) were detected by Grubbs' and Tietjer-Moore tests, thus all available data were used in our meta-analyses (Table S4). Acute, developmental, reproductive, and neurological CTDs were subsequently generated for rat (oral, dermal, and inhalation; Fig. 1; see Fig. S1 for rat inhalation acute LD50 CTD using data expressed in mg/m³), dog, mouse, and rabbit (oral only; Fig. 2). All datasets passed the Shapiro-Francia (normality of residuals; p > 0.05) and Anderson-Darling tests (p > 0.05; Table S5). Derived TCs and 95% CIs at 1st, 5th, 10th, 50th, 90th, 95th, and 99th percentiles were listed in Table 2.

Using TC5s as examples, neonicotinoids tended to be acutely lethal to rats at or below 56 (95% CI: 22, 99), 1583 (1172, 1777), and 451 (294, 615) mg/kg bw/day for 5% of chemicals under oral, dermal, and inhalation exposures, respectively. Comparatively, there were 5%

probability of neonicotinoids to elicit chronic developmental and reproductive responses (LOAELs) to rat (oral) at or below 1.7 (0.76, 3.2) and 4.2 (0.01, 20) mg/kg bw/day, respectively, and corresponding TC5s using NOAELs were estimated at 0.11 (0.02, 0.36) and 0.23 (0.001, 3.2) mg/kg bw/day. Although rodent neurological hazard data are limited, acute TC5s can still be estimated at 2.7 (0.94, 5.6) and 0.71 (0.25, 1.6) mg/kg bw/day using LOAELs and NOAELs, respectively.

Since dermal and inhalation data were scarce for other species, only oral CTDs were generated for dog (developmental subchronic and chronic NOAELs), mouse (acute LD50s, developmental subchronic and chronic NOAELs/LOAELs), and rabbit (developmental subacute NOAELs/LOAELs; Fig. 2). Accordingly, when considering developmental responses, chronic TC5s were estimated at 2.4 (1.4, 3.2) for dog (using NOAELs only) and 0.75 (0.01, 3.3) and 0.66 (0.24, 1.2) mg/kg bw/day for mouse (using LOAELs and NOAELs), respectively, and subacute TC5s of 17 (9.4, 24) and 5.9 (0.20, 14) mg/kg bw/day were estimated for rabbit using LOAELs and NOAELs, respectively (Table 2).

The use of CTD in PHA can support screening level risk assessment for risk practitioners or assessors with a criterion threshold value to protect a given level (e.g., 5%) of effects for chemicals within a particular chemical class (e.g., neonicotinoids) (Wang et al., 2018). These derived TC values (e.g., TC5) and 95% CIs may serve directly as initial TTCs or adjusted by a factor (e.g., 10-fold) for a species exposed to neonicotinoids under a given exposure scenario (e.g., rat oral developmental/reproductive chronic NOAEL). The TCs (or TC ratios) and their 95% CIs derived from the pairwise CTDs can also be used to compare relative sensitivity between or among different distributions (Solomona et al., 2000; Wang et al., 2018). For example, TC5 ratios and 95% CIs (as demonstrated below) were used in this study to compare relative sensitivities between model species (rat to dog, mouse, or rabbit) or between exposure routes of interest (oral to dermal or inhalation). In addition, the exceedance profile that describes the probability of a class of chemicals such as neonicotinoids exceeding the concentration associated with a particular degree of effect can be estimated practically from the derived log-normal regression functions (e.g., y = ax + b; Table 2).

The TTC concept is an alternative approach in health risk assessment that can be used in the absence of chemical-specific toxicity data. This approach is based on establishing the levels of mammal/human doses for a chemical (a TTC) that would not present a safety concern using toxicity data from other chemicals sharing similar structures (Kroes et al., 2005; Munro et al., 2008; EFSA, 2016). After its initial application by US FD&C Act (1958) with a TTC-like approach for chemicals in food additives in the U.S., it has been adopted to evaluate chemical classes, such as food additives and food contact articles by US FDA (1995) and ILSI Europe (Kroes et al., 2004; Barlow, 2005), flavoring substances by EFSA (EC, 2000; EFSA, 2010) and JECFA (1995), industrial chemicals by ECETOC (2004), and genotoxic impurity by EMA (2006). The TTC and other TTC-like approaches (e.g., dermal sensitization threshold (DST) for dermal and concentration of no toxicological concern (CoNTC) for inhalation) were also applied for assessing chemicals introducing dermal and inhalation toxicity, such as skin sensitizing substances (Api et al., 2008; Keller et al., 2009; Safford et al., 2011) and air pollutants (Drew and Frangos, 2007; Escher et al., 2010).

Our study also incorporated the TTC concept in hazard assessment of neonicotinoids to multiple mammalian species and exposure routes, and a number of TCs and 95% CIs for mammalian species under comparative exposure scenarios against neonicotinoids were derived (oral, dermal, and inhalation; Table 2). Those TC values (e.g., TC1 or TC5) or their lower-bound of 95% CIs may be useful as initial TTCs for neonicotinoids during regulatory applications. For example, if TC1 of 0.11 mg/kg bw/day derived from developmental chronic NOAEL CTD was borrowed as an overall PoD and adopted by a 100-fold UF (accounting inter- and intra-species variances), an interim HLV of 0.001 mg/kg bw/day was derived. Until more robust toxicology





4

.

0

Concentration (log, mg/kg bw/day)



Table 2 Threshold concentrati	ions (TCs) and t	heir 95%	confidence in	ttervals (95°	% CIs) a	ıt 1 st , 5 ^t	^h , 10 th , 5	50 th , 90 th , 95 th	, and 99 th perce	ntiles for each	chemical to	cicity distribution	(CTD) considering a	ll chemicals.
CTDs	Exposure	Specie	Exposure	Unit	п у=	a x + b		TC1 (95%	TC5 (95% CI)	TC10 (95%	TC50 (95%	TC90 (95% CI)	TC95 (95% CI)	TC99 (95% CI)
	duration		route		а	q	R^2	5		Ē	Ē			
Acute LD50	Acute	Rat	Oral	mg/kg bw/dav	9 50.	6 -94.	906.0	20 (5.5, 43)	56 (22, 99) a	98 (46, 157)	697 (512, 035)	4981 (3064, 10 321)	8698 (4855, 21 430)	24,746 (11,385, 85,968)
		Rat	Dermal	mg/kg	8 387	-12	4 0.754	1379 (908,	1583 (1172,	1703 (1344,	2205 (2071,	10,341) 2856 (2607,	21,439) 3073 (2753, 4225)	3526 (3041, 5476)
				bw/day				1611)	1777) b	1875)	2363)	3691)		
		Rat	Inhalation	mg/kg	7 82.	3 -22	4 0.932	236 (131,	451 (294,	636 (453,	2152 (1851,	7278 (5671,	10,280 (7614,	19,650 (13,028, 36,206)
				bw/day				362)	615) c	821)	2464)	10,443)	16,039)	
				mg/m ³	7 82.	3 - 22	7 0.932	254 (143,	486 (322,	687 (495,	2322 (1988,	7852 (6112,	11,091 (8153,	21,199 (13,967, 39,415)
		Moneo	[0	ma Ara	г г	01- 0	1 0.040	389)	602) 61 (24 00) 2	885) 104/40 152)	2676) 690 (507	11,296) 4444 (3784	I7,306) 7560 (1231	JU E47 (0762 63 000)
		Denotat	0141	bw/day	5			24 (0.4, 40)	01 (24, 20) a	101 (12, 100)	864)	8353) 8353)	16,711)	20,042 (7/ 00, 02,000)
Developmental NOAEL	Subacute	Rat	Oral	mg/kg bw/dav	5 66.	0 - 40.	5 0.961	1.3 (0.6, 2.3)	3.1 (1.7, 4.6)	4.9 (3.0, 6.7)	24 (20, 28)	114 (82, 187)	178 (119, 331)	412 (236, 987)
		Rabbit	Oral	mg/kg	5 72.	7 -63.	2 0.754	2.8 (0.02,	5.9 (0.20, 14)	8.8 (0.59, 18)	36 (24, 67)	149 (92, 1356)	222 (122, 4098)	471 (202, 32,457)
				bw/day				8.7)						
	Subchronic	Rat	Oral	mg/kg bw/day	6 54.	6 -21.	2 0.859	0.70 (0.11, 1.8)	1.9 (0.50, 3.8)	3.2 (1.1, 5.7)	20 (15, 30)	128 (73, 352)	217 (110, 760)	579 (232, 3309)
		Dog	Oral	mg/kg	6 41.	2 -8.1	5 0.848	0.3 (0.01,	1.1 (0.12, 3.5)	2.2 (0.4, 5.8)	26 (17, 52)	303 (143, 2012)	609 (245, 6420)	2256 (652, 55,917)
		Monoo	10.0	DW/ UAY	26 3	7 1 16	0000	1.4) 0.09 (0.003	0 64 70 06	1 E (0.99	(101 00) 01	101 (704	072176719	43 404 (73E3
		INIOUSE	Oral	mg/kg hur/dour	0	cI.I /	0.880	0.08 (0.003,	, eu.u) +e.u	1.3 (U.23,	08 (32, 131)	2191 (/84, 15 619)	0142(1/49, 71140)	42,494 (/332, 1 110 407)
					LC V	1 20		0.04)	2.5) 7.010	3.U) 1 1 /0 20	(10 01) 01	13,012) 224 (170 0F0)	/1,144) 750/007 0700)	1,210,40/)
	Curonic	Kat	Urai	mg/kg bw/dav	0 20	5.4. c	776.0	0.36)	0.50 (0.13, 1.2) a	1.1 (0.38, 2.3)	19 (13, 31)	334 (1/0, 938)	/20 (32/, 2/83)	3410 (1100, 20,200)
		Dog	Oral	mg/kg	6 73.	5 - 35.	6 0.967	1.2 (0.6, 1.7)	2.4 (1.4, 3.2) L	3.6 (2.4, 4.6)	15 (12, 17)	59 (44, 85)	88 (61, 140)	184 (115, 356)
		Monto	lerO	bw/ day	с 36	2 6	0 0 0 20	0 1 1 (0 04	D 0 66 (0 34	1 E (D 6E	97 (10 3E)	177 (765 000)	1068 (522 9796)	1036 (1041 18 476)
		MIOUSE	OTA	mg/kg bw/day	0 0	0.1 - C	0.4.0 6	0.33)	0.00 (0.24, 1.2) a	1.5 (0.05, 2.4)	(66,41) /2	412 (203, 490)	1000 (222, 2/20)	49.30 (1.94.1, 10,4/0)
Developmental LOAEL	, Subacute	Rabbit	Oral	mg/kg bw/day	5 80.	5 -10	5 0.936	8.3 (3.7, 14)	17 (9.4, 24)	24 (15, 32)	86 (71, 102)	311 (231, 532)	448 (310, 869)	888 (533, 2207)
	Subchronic	Rat	Oral	mg/kg	5 44.	5 - 42.	1 0.746	1.7 (0.002,	6.0 (0.05, 23)	12 (0.3, 36)	118 (58, 204)	1207 (530, 45 240)	2332 (838, 242 205)	8030 (1886, 5,057,791)
	Chronic	Rat	Oral	mg/kg	6 35.	4 -15.	1 0.964	0.37 (0.12.	1.7 (0.76, 3.2)	3.9 (2.0, 6.5)	50-1) 69 (53, 93)	1229 (751, 2326)	2778 (1529, 6167)	12,827 (5692, 38,212)
				bw/day				0.88)						
		Mouse	Oral	mg/kg	5 27.	3 -4.1	0.787	0.10 (0.001,	0.75 (0.01,	2.2 (0.02,	97 (22, 236)	4272 (697,	12,501 (1386,	93,692 (5215,
				bw/day				0.87)	3.3)	7.1)		1,413,544)	19,631,546)	2,202,875,318)
Reproductive NOAEL	Chronic	Rat	Oral	mg/kg	6 36.	5 -4.9	1 0.600	0.23 (0.001,	0.97 (0.001,	2.1 (0.001,	32 (11, 248)	490 (149, 1627)	1063 (251, 5348)	4533 (605, 49,066)
Reproductive LOAEL	Chronic	Rat	Oral	bw/day mg/kg	5 41.	5 - 33.	0 0.722	3.2) 1.1 (0.001,	7.3) 4.2 (0.01, 20)	12) 8.4 (0.07, 31)	101 (43,	1201 (492, 9342)	2426 (800, 60,757)	9073 (1917, 216,156)
4				bw/day				8.8)		n r	316)	к Т		к х х
Neurological NOAEL	Acute	Rat	Oral	mg/kg hw/dav	5 33.	4 -2.9	6 0.972	0.13 (0.03,	0.71 (0.25, 1 6)	1.7 (0.77, 3 4)	39 (29, 58)	874 (537, 2417)	2115 (1136, 7306)	11,102 (4555, 59,758)
Neurological LOAEL	Acute	Rat	Oral	mg/kg bw/dav	6 36.	2 - 22.	5 0.956	0.59 (0.14, 1.6)	2.7 (0.94, 5.6)	5.9 (2.6, 11)	101 (72, 145)	1711 (976, 4317)	3821 (1934, 12.048)	17,238 (6787, 81,753)

Uncertainty factors (UFs) de	rived from chemical toxicity dist	tribution (CTD) con	nparisons (i.e., threshold conce	ntration 5% (TC5) ratios), wh	lereas the both datasets consisting o	all chemicals.
1) UFs within a species (oral)						
TC5 ratio (95% CI)	Developmental subacu	ute NOAEL I	Developmental subchronic NOAEL	Developmental chronic l	VOAEL Reproductive chronic N	DAEL Neurological acute NOAEL
Acute LD50	Rat: 18 (6.4, 42)	H	tat: 24 (8.2, 62) Jourse: 113 (21-1438)	Rat: 112 (32, 464) Mouse: 92 (30-295)	Rat: 58 (5.8, 858)	Rat: 79 (23, 253)
Developmental subacute NOA Developmental subchronic NC	EL AEL		tat: 1.7 (0.6, 6.4)	Rat: 6.2 (2.0, 24) Rat: 6.2 (2.0, 24) Rat: 3.8 (0.7, 17) Dog: 0.4 (0.05, 1.6) Mouser 0.8 (0.06, 4.0)		
Developmental subacute LOAI Developmental subchronic LO	L. Rabbit: 2.8 (0.9, 57) AEL	H	tat: 3.2 (0.1, 22)	Bat: 3.4 (1.0.15)		
Reproductive chronic LOAEL					Rat: 4.3 (0.01, 143) Mouse: 1.1 (0.01, 8.6)	
Neurological acute LOAEL						Rat: 3.7 (1.0, 14)
2) UFs for species-to-species a	nd route-to-route extrapolations					
TC5 ratio (95% CI)		Acute LD50s	Developmental	subacute NOAEL	Developmental subchronic NOAEL	Developmental chronic NOAEL
Species-to-species	Rat-to-dog (oral) Rat-to-mouse (oral)	0.9 (0.3, 2.7)			0.8 (0.2, 1.9) 3.5 (0.5, 43)	0.5 (0.08, 5.1) 0.8 (0.2, 3.0)
Route-to-route	Rat-to-rabbit (oral) Oral-to-dermal (rat) Oral-to-inhalation (rat)	0.04 (0.01, 0. 0.1 (0.05, 0.3	0.5 (0.2, 14) 07)			

Table 3 Uncertaint

16

TC5 ratio (95% CI)	al)						
	Developmental subacu	e NOAEL Developme	ental subchronic NOAEL	Developmental chronic l	VOAEL Reproductive chroi	nic NOAEL	Neurological acute NOAEL
Acute LD50	Rat: 20 (4.0, 58)	Rat: 35 (5. Moneo: 11	.2, 100) 3 (21 1438)	Rat: 159 (22, 707) Mouse [,] NA	Rat: 82 (4.8, 681)		Rat: 64 (13, 230)
Developmental subacute N Developmental subchronic	OAEL NOAEL	Rat: 1.0 (0	.4, 2.9)	Rat: 3.0 $(1.4, 9.0)$ Rat: 3.8 $(0.7, 17)^{a}$ Door 0.4 $(0.05, 1.6)^{a}$			
				Mouse: 0.4 (0.01, 3.6)			
Developmental subacute LA Developmental subchronic	DAEL Rabbit: 2.8 (0.9, 57) ^a LOAEL	Rat: 2.9 (0	1, 12)				
Developmental chronic LO Reproductive chronic LOAI	AEL EL			Rat: 3.4 (1.0, 15) ^a	Rat: 5.0 (0.01, 825	()	
Neurological acute LOAEL					Mouse: 1.1 (0.01, 8	8.6) ^a	Rat: NA
2) UFs for species-to-specie	es and route-to-route extrapolations						
TC5 ratio (95% CI)		Acute LD50s	Developmental subs	acute NOAEL	Developmental subchronic NOAEL		evelopmental chronic NOAEL
Species-to-species	Rat-to-dog (oral) Rat-to-mouse (oral)	1.5 (0.2, 5.2)	VIN		$0.8 (0.2, 1.9)^{a}$ $3.5 (0.5, 43)^{a}$	0 0	.5 (0.08, 5.1) ^a .6 (0.1, 2.2)
Route-to-route	var-to-tabut (viat) Oral-to-dermal (rat) Oral-to-inhalation (rat)	0.03 (0.008, 0.07) 0.2 (0.04, 0.5)	- ANI				





2

0

7

UFs (log)





2

0

÷

2

UFs (log)

normal fitted distr	s (Urs) delived month	unviauai Ur proba	חזווע מוווע	IDULIO	וא מו אטוו.	, 90UL, 6	וות אשנוו הבוכבו	TITIES THE DETCEN	id Sillad strint to sall	JIECTEU ULIUEI UEIAULI OF UL AII	מ דוטו שבוב מואט מבווזיכם וויטוו במכוו וטל-
1) UFs within a sp	ecies (oral)										
UFs			Species n	1 y = 1	a x + b		90th (95%	95th (95% CI)	99th (95% CI)	% of NNIs being protect under	% of NNIs being protect under default
				а	q	R^2	CI)			default UF of 10	UF of 100
LD50-to-NOAEL	Acute LD50-to-develoF NOAFI.	pmental subacute	Rat	5 78.3	- 69.8	0.943	127 (93, 206)	185 (125, 335)	373 (220, 840)	11%	85%
	Acute LD50-to-develor NOAFL	pmental subchronic	Rat (5 58.0	- 64.8	0.892	186 (130, 380)	281 (179, 691)	608 (326, 2061)	9.0%	76%
			Mouse 5	5 28.6	26.5	0.881	242 (87, 3851)	673 (189, 20 806)	4563 (775, 573,455)	55%	83%
	Acute LD50-to-develor NOAFI	pmental chronic	Rat (5 48.3	- 31.8	0.977	411 (280, 623)	749 (475, 1277)	2311 (1265, 4921)	16%	66%
	Acute LD50-to-reprodu	active chronic	Rat (5 48.8	- 22.0	0.940	246 (141, 547)	447 (231, 1233)	1370 (571, 5618)	25%	76%
	NUAEL Actite LD50-to-netitolo	voical acute NOAFI.	Rat	629	- 24 4	0 925	547) 78(52-130)	124 (75 243)	296 (150, 800)	37%	03%
Exposure duration	Developmental subacu NOAEL	ite-to-subchronic	Rat	72.0	34.0	0.591	6.9 (3.6, 7801)	10 (4.7, 98,909)	22 (7.2, 11,307,051)	94%	%66 <
	Developmental subacu NOAEL	ite-to-chronic	Rat	5 221	-21.9	0.970	3.4 (3.1, 4.0)	3.9 (3.5, 4.8)	5.0 (4.3, 6.7)	> 99%	> 99%
	Developmental subchn	onic-to-chronic	Rat (5 71.9	48.7	0.901	4.4 (2.7, 10)	6.6 (3.7, 19)	14 (6.7, 59)	97%	> 99%
	NOAEL		Dog (5 40.6	40.0	0.975	22 (14, 41)	45 (25, 98)	174 (80, 508)	81%	67%
			Mouse 5	5 25.3	42.4	0.910	114(40, 590)	359 (100, 2862)	3094 (549, 55,278)	69%	89%
LOAEL-to-NOAEL	Developmental subacu NOAEL	ite LOAEL-to-	Rabbit E	5 128	1.71	0.922	5.4 (4.3, 8.5)	6.8 (5.1, 12)	10 (7.1, 23)	98%	> 99%
	Developmental subchr NOAEL	onic LOAEL-to-	Rat	5 110	- 24.9	0.961	12 (10, 16)	16 (13, 22)	27 (20, 40)	83%	∾66 <
	Developmental chronic	c LOAEL-to-NOAEL	Rat é	5 260	- 93.6	0.887	5.3 (4.8, 6.7)	5.9 (5.2, 7.9)	7.3 (6.1, 11)	> 99%	%66 <
	Reproductive chronic l	LOAEL-to-NOAEL	Rat 5	5 153	-13.8	0.925	5.1 (4.3, 6.7)	6.2 (5., 8.6)	8.9 (6.7, 14)	> 99%	> 99%
			Mouse	5 23.9	36.6	0.901	274 (75, 3508)	934 (190, 21,417)	9296 (1090, 742,476)	61%	83% 8
2) UFs for species-	-to-species and route-to-r	oute extrapolations									
UFs		Endpoints		и	y = a x	q +	90th (95%	95th (95% CI)	99th (95% CI)	% of NNIs being protect under	% of NNIs being protect under default
					a b	R^2	<u>3</u>			default UF of 10	UF of 100
Species-to-species	Rat-to-dog (oral)	Developmental sul NOAEL	chronic	9	95.1 6	0.2 0.9	50 2.3 (1.8, 3	2) 3.1 (2.3, 4.8)	5.5 (3.7, 10)	%66 <	> 99%
		Developmental chr	onic NOAE	9 t	35.3 4	5.7 0.9	48 25 (12, 91) 30 15 (0.0 35)	57 (23, 288)	272 (81, 2573)	81%	97%
	kat-to-mouse (oral)	Acute LUCOS Developmental sul NOAEL	schronic	9	46.1 7	2.0 0.1 1.0 0.1	00 19 0.9 0. 30 82 3.2 (2.7, 4.) 29 (16, 80) 3) 5.9 (4.7, 8.3)	19 (14, 28) 19 (14, 28)	65.% 97%	> 99%
		Developmental chi	onic NOAE	ы С	24.4 5	2.0 0.9	12 59 (17, 589	 199 (42, 3889) 	1925 (221, 134,456)	77%	92%
Route-to-route	Oral-to-dermal (rat) Oral-to-inhalation (rat)	Acute LD50s Acute LD50s		8	48.7 7 127 9	2.2 0.8 0.9 0.9	63 2.7 (1.5, 7. 61 1.1 (0.9, 1.	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	15 (5.5, 78) 2.0 (1.6, 3.2)	98% 97%	%66 < %66

Z. Wang et al.

Table 5

information becomes available, this interim HLV could be adequately protective for the six commonly used neonicotinoids (acetamiprid, clothianidin, dinotefuran, imidacloprid, thiacloprid and thiamethoxam; Table 1) around the globe.

3.3. Uncertainty factors (UFs)

Most pairwise log-normal CTDs using all (Figs. S2 and S3) and common (Figs. S4 and S5) neonicotinoids visually diverged, indicating different sensitivity. This observation was further supported by significantly different slope and/or intercept parameters (Tables S6 and S7). Using the CTD comparisons approach, 18 UFs were identified for a single species (12, 4, 1 and, 1 for rat, mouse, dog, and rabbit, respectively) including LD50-to-NOAEL, exposure durations, and LOAEL-to-NOAEL extrapolations using all hazard data (Tables 3 and S8). Concurrently, additional UFs were identified using CTD comparisons for both datasets having similar neonicotinoids (except rat neurological acute LOAEL-to-NOAEL and mouse acute LD50-to-developmental chronic NOAEL TC ratios (n < 5) and five UFs for pairwise datasets having similar neonicotinoids; Tables 4 and S9). Corresponding TC values for the pairwise CTDs contained similar neonicotinoids were estimated (Table S10). Probability distributions were also constructed using all calculated UFs for individual neonicotinoids from the pairwise datasets (Figs. 3 and 4), and overall UFs covering 90%, 95%, and 99% of neonicotinoid chemicals of concern were estimated (Table 5). Meanwhile, probability of encountering each UF for neonicotinoids above or below common factors of 10 or 100 were determined (Table 5).

The UFs are not always applied to chronic NOAELs for toxicity endpoints of concern; rather, UFs represent alternative choices when ideal hazard information is not available. It is also crucial to evaluate uncertainties during hazard and risk assessment, as it directly impacts risk management measures (US EPA, 1995). Despite LD50s not commonly being used in mammalian hazard assessment, the values are sometimes used as a starting point and then adjusted by a larger ACR in an emergency situation or in a screen-level risk assessment, particularly when there are no other types of data available (e.g., State of Michigan) (State of Michigan, 2017). However, the suitability of applying such default ACRs needs to be examined for various chemical classes. As shown in Table S3, there were acute LD50s available for imidaclothiz and nitenpyram, yet developmental or reproductive toxicity information for these insecticides are lacking. If rodent acute LD50s are used as surrogates and divided by a factor of 10 (or 100), the derived chronic developmental or reproductive toxicity profiles (NOAELs) would only provide 16% (or 66%) or 25% (or 76%) of protection (Table 5). Instead, during the present study ACRs of 112 (32, 464) (TC5 ratio)-411 (280, 623) (90th centile) and 58 (5.8, 858)-246 (141, 547) were estimated for neonicotinoids for rat (oral) from TC5 ratios between acute LD50s and developmental and reproductive chronic NOAELs, respectively (Tables 3-5). In addition, an ACR for mouse (oral) was estimated to be 92 (30, 295) using CTD comparisons approach. Subsequently, such mechanistically derived ACR values may be applied with higher confidence than the arbitrary default values of 10 or 100.

When only subchronic/subacute data are available for an endpoint, an extra exposure duration extrapolation factor (e.g., UF_{S-C}) is normally applied to extrapolate chronic exposure. Within a similar developmental response, UF extrapolations for exposure duration were computed for neonicotinoids, and three 95% CIs of four TC5 ratios overlapped with the unity (except for rodent oral developmental subacuteto-chronic UF of 6.2 (2.0, 24) and 3.0 (1.4, 9.0) using all and common neonicotinoids, respectively; Tables 3 and 4), indicating similar sensitivity for particular endpoints of a species across exposure durations. Interestingly, UF_{S-C} values were species-dependent and were 4.4 (2.7, 10), 22 (14, 41), and 114 (40, 590) for rat, dog, and mouse, respectively, when considering developmental toxicity data from individual UF probability distribution. It appears UF_{S-C} could be reduced from 10 to 3.8–4.4 for rats (oral), again based on existing information, since a factor of 10 would provide adequate protection with high confidence (97%; Table 5) when rodent developmental subchronic NOAELs were used as surrogates for chronic NOAELs. Similarly, it may be reasonable to reduce UFs for subacute-to-subchronic and subacute-to-chronic extrapolations from 10 to 1.0–6.9 and 3.0–6.2, respectively, for rats (oral) when considering developmental responses. This observation was similar with previous studies (Rulis and Hattan, 1985; Lewis, 1993; Dourson et al., 1996) that 10-fold UF_{S-C} provided sufficient (or over) protection and could be reduced on a scientific basis (warranted smaller UF_{S-C}). Conversely, the UF_{S-C} might be increased from 10 to 22 and 114 for dog and mouse, respective, for extrapolating more conservative chronic NOAELs due to low confidence of protection using a 10-fold UF (82% for dog and 69% for mouse; Table 5).

The UF_{L-N} is another UF applied to LOAELs to estimate NOAEL values. Numerous studies suggested reducing this factor from 10 to lower values (e.g., 2–3 by ECETOC (1995)) for particular chemical classes in practice (Naumann and Weideman, 1995; Dourson et al., 1996; Wang et al., 2018). Based on existing information for neonicotinoids (Tables 3–5), it appears reasonable (with high confidence) to reduce UF_{L-N} from 10 to 3.4–5.3, 4.3–5.1 and 3.7 when considering developmental (chronic), reproductive (chronic), and neurological (acute) LOAELs, respectively, as surrogates for corresponding NOAEL for rats, and 2.8–5.4 for rabbits when using developmental subacute LOAELs for NOAELs. However, it is exceptionally important to note that a larger UF_{L-N} of 247 was identified to be more appropriate for mouse (oral) when considering developmental chronic responses.

In the case that relevant data are deficient for a species or an exposure route of interest, health risks resulting from dermal or inhalation exposures are frequently assessed based on rodent oral toxicity data (Freireich et al., 1966; Geraets et al., 2014). For neonicotinoids, differences in data deficiency were remarkable. While dermal and inhalation data were limited, rodent oral hazard data dominated the datasets (Tables S3 and S4). In the case of species-to-species extrapolations, six UFs were derived from rat to dog, mouse, and rabbit considering all available oral acute LD50s, and developmental subacute, subchronic, and chronic NOAELs (Tables 3 and S8; five UFs when considering common neonicotinoids for both datasets; Tables 4 and S9). Surprisingly, calculated UFs for species-to-species extrapolation on the basis of TC5 ratios were all equal to 1, implying there were no significant differences in sensitivity between rat and mouse (developmental subchronic/chronic), rat and dog (developmental subchronic/ chronic), neither rat and rabbit (acute). For purposes of conservatism, UFs of 2.3 and 25 were identified for rat-to-dog extrapolations when considering development subchronic and chronic responses, respectively. Similarly, UFs of 15, 3.2, and 59 could be useful for rat-to-mouse extrapolations when considering acute (lethal) and developmental subchronic and chronic effects, respectively.

Because there were only sufficient rodent data (acute LD50s) of neonicotinoids for constructing dermal and inhalation CTDs, oral-todermal and oral-to-inhalation UFs were identified for rats (Tables 3-5). Interestingly, it appears that rodent oral LD50s were often smaller than dermal and inhalation LD50s (left shifted oral CTDs to corresponding dermal/inhalation CTDs; Figs. S3g and h and S5g and h), indicating that rats were more sensitive to neonicotinoids under oral exposure than dermal or inhalation exposures, which avoid first pass metabolism. This observation was characterized by the smaller than 1 TC5 ratios (Tables 3 and 4) and individual UFs (87.5% for oral-to-dermal and 100% for oral-to-inhalation; Fig. 4). Thus, based on the analysis presented here, rodent oral hazard data appears to provide sufficient protection if they are used for inhalation extrapolation, with a factor of 2.7 could be recommended for rodent oral-to-dermal extrapolation (Table 5). Further studies should be conducted when additional dermal or inhalation chronic responses (especially for rabbit) are available to compare the corresponding rodent oral CTDs for a particular response. Further metaanalysis should also be conducted when more hazard data are available,

especially for imidaclothiz, nitenpyram, nithiazine, and paichongding, so as to validate and/or refine our current findings.

4. Conclusions

In the present meta-analysis paper, we reviewed and examined public available hazard data for mammal species (rat, dog, mouse, and rabbit) under oral/dermal/inhalation exposures against neonicotinoids. The PHA approach using CTDs for neonicotinoids was subsequently conducted and corresponding TC and 95% CI values were estimated for a particular dataset under a defined exposure scenario for various common mammalian species. These threshold concentrations from a more robust dataset on a data-driven basis can benefit read across when filling data gaps or conducting screening-level risk assessment for neonicotinoids in the future.

In practice, these derived TCs (or adjusted by a factor) represent initial TTC values for future hazard and risk assessment, or could be useful as surrogates for interim HLVs establishment. These thresholds of neonicotinoids and probability values (likelihood of adverse health effects) are also becoming increasingly important in upper-tier risk assessment. Using available hazard data, uncertainty factors were also identified for neonicotinoids including LD50-to-NOAEL, LOAEL-to-NOAEL, and exposure duration extrapolations within a species, in addition to species-to-species (oral: rat-to-dog/mouse/rabbit) and routeto-route (rats: oral-to-dermal/inhalation) extrapolations. These identified UFs, which can be refined with more data availability, appear beneficial for risk practitioners during data dossier development (read across) or conducting screening-level risk assessment especially for neonicotinoids with little or no toxicity information. Risk assessors or managers can also characterize potential hazard of neonicotinoids using these data-driven UFs, which reflect degrees of uncertainty in various cases and inform influences of uncertainty during risk management decisions with additional scientific judgment.

Acknowledgements

This work was supported by the National Science Foundation of China (41773101 and 41473106) and Department of Science and Technology of Guangdong Province (2017A030313065, 2015TX01Z168 and 2015A030310219).

Conflict of interest

The authors declare no conflicts of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.envint.2019.01.040.

References

- Abou-Donia, M.B., Goldstein, L.B., Bullman, S., Tu, T., Khan, W.A., Dechkovskaia, A.M., Abdel-Rahman, A.A., 2008. Imidacloprid induces neurobehavioral deficits and increases expression of glial fibrillary acidic protein in the motor cortex and hippocampus in offspring rats following in utero exposure. J. Toxicol. Environ. Health A 71, 119–130.
- Anderson, T.W., Darling, D.A., 1954. A test of goodness of fit. J. Am. Stat. Assoc. 49, 765–769.
- Api, A.M., Basketter, D.A., Cadby, P.A., Cano, M.F., Ellis, G., Gerberick, G.F., Griem, P., McNamee, P.M., Ryan, C.A., Safford, R., 2008. Dermal sensitization quantitative risk assessment (QRA) for fragrance ingredients. Regul. Toxicol. Pharmacol. 52, 3–23.
- Barlow, S., 2005. Threshold of Toxicological Concern (TTC): A Tool for Assessing Substances of Unknown Toxicity Present at Low Levels in the Diet. ILSI Europe Concise Monograph Series ILSI Press, Brussels, Belgium.
- Berninger, J.P., Brooks, B.W., 2010. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol. Lett. 193, 69–78.
- Berninger, J.P., Williams, E.S., Brooks, B.W., 2011. An initial probabilistic hazard assessment of oil dispersants approved by the United States National Contingency Plan.

Environ. Toxicol. Chem. 30, 1704-1708.

- Bide, R.W., Armour, S.J., Yee, E., 2000. Allometric respiration/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans. J. Appl. Toxicol. 20, 273–290.
- Chen, M., Tao, L., McLean, J., Lu, C., 2014. Quantitative analysis of neonicotinoid insecticide residues in foods: implication for dietary exposures. J. Agric. Food Chem. 62, 6082–6090.
- Commonwealth of Australia, 2017. Acceptable Daily Intakes (ADI) for Agricultural and Veterinary Chemicals Used in Food Producing Crops or Animals. Australian Pesticide and Veterinary Medicines Authority, Australian Government.
- Dobbins, L.L., Brain, R.A., Brooks, B.W., 2008. Comparison of the sensitivities of common in vitro and in vivo assays of estrogenic activity: application of chemical toxicity distributions. Environ. Toxicol. Chem. 27, 2608–2616.
- Dobbins, L.L., Usenko, S., Brain, R.A., Brooks, B.W., 2009. Probabilistic ecological hazard assessment of parabens using *Daphnia magna* and *Pimephales promelas*. Environ. Toxicol. Chem. 28, 2744–2753.
- Dourson, M.L., Felter, S.P., Robinson, D., 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108–120.
- Dreier, D.A., Connors, K.A., Brooks, B.W., 2015. Comparative endpoint sensitivity of in vitro estrogen agonist assays. Regul. Toxicol. Pharmacol. 72, 185–193.
- Drew, R., Frangos, J., 2007. The concentration of no toxicological concern (CoNTC): a risk assessment screening tool for air toxics. J. Toxicol. Environ. Health A 70, 1584–1593.
- EC, 2000. Commission regulation (EC) No. 1565/2000 of 18 July laying down the measures necessary for the adoption of an evaluation programme in application of Regulation (EC) No. 2232/96 of the European Parliament and of the Council. Off. J. Eur. Communities L180/8–L180/16 19.7.2000, Annex I.
- EC, 2004. Commission Directive 2004/99/EC of 1 October 2004 amending Council Directive 91/414/EEC to include acetamiprid and thiacloprid as active substances. Off. J. Eur. Union 309, 6–8.
- EC, 2005. Review report for the active substance clothianidin. Finalised in the Standing Committee on the Food Chain and Animal Health at its meeting on 27 January 2006 in view of the inclusion of clothianidin in Annex I of Directive 91/414/EEC. In: Directorate D - Food Safety: Production and Distribution Chain Unit D.3 - Chemicals, Contaminants and Pesticides. Health & Consumer Protection Directive-General, Europen Commision.
- EC, 2006. Review report for the active substance thiamethoxam. Finalised in the Standing Committee on the Food Chain and Animal Health at its meeting on 14 July 2006 in view of the inclusion of thiamethoxam in Annex I of Directive 91/414/EEC. In: Directorate D -Safety of the Food Chain. Unit E.3 - Chemicals, Contaminants, Pesticides. Health & Consumer Protection Directive-General. Europen Commision.
- EC, 2014. Regulation (EU) No 528/2012 concerning the making available on the market and use of biocidal products. In: Evaluation of Active Substances, Assessment Report. Dinotefuran Product-type 18 (Insecticides, Acaricides and to Control Other Arthropods) 17 June 2014. Assessment Report. UK.
- EC, 2015. Final review report for the active substance imidacloprid. Finalised in the Standing Committee on the Food Chain and Animal Health at its meeting on 26 September 2008, in view of the inclusion of imidacloprid in Annex I of Directive 91/ 414/EEC. In: Safety of the Food Chain, Pesticides and Biocides. Directive-General for Health and Food Safety, Europen Commision.
- EC, 2017. Final renewal report for the active substance acetamiprid, finalised in the Standing Committee on Plants, Animals, Food and Feed at its meeting on 13 December 2017, in view of the renewal of the approval of acetamiprid as active substance in accordance with Regulation (EC) No 1107/2009. In: Food and Feed Safety, Innovation, Pesticides and Biocides. Directive-General for Health and Food Safety, Europen Commision.
- ECETOC, 1995. Assessment Factors in Human Health Risk Assessment. Technical Report, No. 68. European Center for Ecotoxicology and Toxicology of Chemicals (ECETOC), Brussels, Belgium.
- ECETOC, 2004. Targeted Risk Assessment. Technical Report No. 93. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium.
- EFSA, 2010. Guidance on the data required for the risk assessment of flavourings to be used in or on foods. EFSA J. 8, 1623.
- EFSA, 2013. Scientific opinion of the PPR panel on the developmental neurotoxicity potential of acetamiprid and imidacloprid. EFSA J. 11, 3471.
- EFSÅ, 2016. Review of the Threshold of Toxicological Concern (TTC) Approach and Development of New TTC Decision Tree. EFSA (European Food Safety Authority) Supporting Publication 2016: EN-1006. pp. 50.
- EMA, 2006. Guideline on the Limits of Genotoxic Impurities. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), CPMP/SWP/ 5199/02, EMEA/CHMP/QWP/251344/2006, London, UK.
- Escher, S.E., Tluczkiewicz, I., Batke, M., Bitsch, A., Melber, C., Kroese, E.D., Buist, H.E., Mangelsdorf, I., 2010. Evaluation of inhalation TTC values with the database RepDose. Regul. Toxicol. Pharmacol. 58, 259–274.
- Freireich, E.J., Gehan, E.A., Rall, D.P., Schmidt, L.H., Skipper, H.E., 1966. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219–244.
- Geraets, L., Bessems, J.G.M., Zeilmaker, M.J., Bos, P.M.J., 2014. Human risk assessment of dermal and inhalation exposures to chemicals assessed by route-to-route extrapolation: the necessity of kinetic data. Regul. Toxicol. Pharmacol. 70, 54–64.
- Goulson, D., 2013. Review: an overview of the environmental risks posed by neonicotinoid insecticides. J. Appl. Ecol. 50, 977–987.
- Grubbs, F.E., 1969. Procedures for detecting qutlying observations in samples. Technometrics 11, 1–21.

 Han, W.C., Tian, Y., Shen, X.M., 2018. Human exposure to neonicotinoid insecticides and the evaluation of their potential toxicity: an overview. Chemosphere 192, 59–65.
 Health Canada, 2007. Proposed Registration Decision PRD2007-02, Thiacloprid. Pest Management Regulatory Agency (PMRA). Health Canada, Canada.

Health Canada, 2010. Proposed Registration Decision PRD2010-02, Acetamiprid. Pest Management Regulatory Agency (PMRA). Health Canada, Canada.

- Health Canada, 2016. Proposed Registration Decision PRVD2016-20, Imidacloprid. Pest Management Regulatory Agency (PMRA). Health Canada, Canada.
- Health Canada, 2017a. Proposed Registration Decision PRD2017-17, Clothianidin. Pest Management Regulatory Agency (PMRA). Health Canada, Canada.
- Health Canada, 2017b. Proposed Registration Decision PRD2017-18, Thiamethoxam. Pest Management Regulatory Agency (PMRA). Health Canada, Canada.
- Hladik, M.L., Main, A.R., Goulson, D., 2018. Environmental risks and challenges associated with neonicotinoid insecticides. Environ. Sci. Technol. 52, 3329–3335.
- JECFA, 1995. Evaluation of certain food additives and contaminants. In: 44th Report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series No. 859 WHO, Geneva, Switzerland.
- Jeschke, P., Nauen, R., Beck, M.E., 2013. Nicotinic acetylcholine receptor agonists: a milestone for modern crop protection. Angew. Chem. 52, 9464–9485.
- JMPR, 2012. Acceptable Daily Intakes, Acute Reference Doses, Short-term and Long-term Dietary Exposures, Recommended Maximum Residue Limits and Supervised Trials Median Residue Values Recorded by the 2012 Meeting.
- JMPR, 2014. Acceptable daily intakes, acute reference doses, short-term and long-term dietary exposures, recommended maximum residue limits and supervised trials median residue values recorded by the 2014 meeting. In: Joint FAO/WHO Meeting on Pesticide Residues. Food and Agriculture Organization (FAO) of the United Nations, World Health Organization (WHO).
- JMPR, 2017. Acceptable daily intakes, acute reference doses, short-term and long-term dietary exposures, recommended maximum residue limits and supervised trials median residue values recorded by the 2017 meeting. In: Joint FAO/WHO Meeting on Pesticide Residues. Food and Agriculture Organization (FAO) of the United Nations, World Health Organization (WHO).
- Keller, D., Krauledat, M., Scheel, J., 2009. Feasibility study to support a threshold of sensitization concern concept in risk assessment based on human data. Arch. Toxicol. 83, 1049–1060.
- Kimura-Kuroda, J., Komuta, Y., Kuroda, Y., Hayashi, M., Kawano, H., 2012. Nicotine-like effects of the neonicotinoid insecticides acetamiprid and imidacloprid on cerebellar neurons from neonatal rats. PLoS One 7, e32432.
- Klarich, K.L., Pflug, N.C., DeWald, E.M., Hladik, M.L., Kolpin, D.W., Cwiertny, D.M., LeFevre, G.H., 2017. Occurrence of neonicotinoid insecticides in finished drinking water and fate during drinking water treatment. Environ. Sci. Technol. Lett. 4, 168–173.
- Kroes, R., Renwick, A.G., Cheeseman, M., Kleiner, J., Mangelsdorf, I., Piersma, A., Schilter, B., Schlatter, J., van Schothorst, F., Vos, J.G., Würtzen, G., 2004. Structurebased thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 42, 65–83.
- Kroes, R., Kleiner, J., Renwick, A., 2005. The threshold of toxicological concern concept in risk assessment. Toxicol. Sci. 86, 226–230.
- Lewis, S.C., 1993. Reducing uncertainty with adjustment factors: improvements in quantitative noncancer risk assessment. Fundam. Appl. Toxicol. 20, 2–4.
- Li, P., Ann, J., Akk, G., 2011. Activation and modulation of human $\alpha 4\beta 2$ nicotinic acetylcholine receptors by the neonicotinoids clothianidin and imidacloprid. J. Neurosci. Res. 89, 1295–1301.
- Mitchell, E.A.D., Mulhauser, B., Mulot, M., Mutabazi, A., Glauser, G., Aebi, A., 2017. A worldwide survey of neonicotinoids in honey. Science 358, 109–111.
- Munro, I.C., Renwick, A.G., Danielewska-Nikiel, B., 2008. The threshold of toxicological concern (TTC) in risk assessment. Toxicol. Lett. 180, 151–156.
- Naumann, B.D., Weideman, P.A., 1995. Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk. Assess. 1, 590–613.
- Rulis, A.M., Hattan, D.G., 1985. FDA's priority-based assessment of food additives. II. General toxicity parameters. Regul. Toxicol. Pharmacal. 5, 152–174.
- Safford, R.J., Aptula, A.O., Gilmour, N., 2011. Refinement of the Dermal Sensitisation Threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains. Regul. Toxicol. Pharmacol. 60, 218–224.
- Seccia, S., Fidente, P., Barbini, D., Morrica, P., 2005. Multiresidue determination of nicotinoid insecticide residues in drinking water by liquid chromatography with electrospray ionization mass spectrometry. Anal. Chim. Acta 2005, 21–26.
- Seccia, S., Fidente, P., Montesano, D., Morrica, P., 2008. Determination of neonicotinoid insecticides residues in bovine milk samples by solid-phase extraction clean-up and liquid chromatography with diode-array detection. J. Chromatogr. A 1214, 115–120.

- Shapiro, S.S., Francia, R.S., 1972. An approximate analysis of variance test for normality. J. Am. Stat. Assoc. 67, 215–216.
- Simon-Delso, N., Amaral-Rogers, V., Belzunces, L.P., Bonmatin, J.M., Chagnon, M., Downs, C., Furlan, L., Gibbons, D.W., Giorio, C., Girolami, V., Goulson, D., Kreutzweiser, D.P., Krupke, C.H., Liess, M., Long, E., McField, M., Mineau, P., Mitchell, E.A.D., Morrissey, C.A., Noome, D.A., Pisa, L., Settele, J., Stark, J.D., Tapparo, A., Dyck, H.V., Praagh, J.V., Van der Sluijs, J.P., Whitehorn, P.R., Wiemers, M., 2015. Systemic insecticides (neonicotinoids and fipronil): trends, uses, mode of action and metabolites. Environ. Sci. Pollut. Res. 22, 5–34.
- Sokal, R.R., Rohlf, F.J., 1995. Biometry, 3rd ed. W.H. Freeman and Company, New York, NY, USA.
- Solomona, K., Giesy, J., Jones, P., 2000. Probabilistic risk assessment of agrochemicals in the environment. Crop Prot. 19, 649–655.
- State of Michigan, 2017. Guidesheet V: Guidance for Providing Toxicity Information to Determine A Rule 2225(5) Standard. http://www.michigan.gov/documents/deq/ wrd-groundwater-p22-toxicity-v_564946_7.pdf.
- Tietjen, G.L., Moore, R.H., 1972. Some Grubbs-type statistics for the detection of several outliers. Technometrics 14, 583–597.
- Tomizawa, M., Casida, J.E., 2005. Neonicotinoid insecticide toxicology: mechanisms of selective action. Annu. Rev. Pharmacol. Toxicol. 45, 247–268.
- US EPA, 1995. Policy for Risk Characterization. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2001. Thiamethoxam 2nd Report of the Hazard Identification Assessment Review Committee. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2002. Pesticide Fact Sheet: Acetamiprid. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2003a. Pesticide Fact Sheet: Clothianidin. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2003b. Pesticide Fact Sheet: Thiacloprid. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2004. Pesticide Fact Sheet: Dinotefuran. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.

US EPA, 2005. Imidacloprid in/on Cranberry; Okra; Popcorn; Watercress; Guava, Papaya, Lychee, Avocado and Related Commodities; Root and Tuber Vegetables (Except Sugar Beets); Leaves of Toot and Tuber Vegetables; Artichoke; Bushberry; Lingonberry; Juneberry; Salal; Legume Vegetables (Except Soybeans); Strawberry and Stonefrit/Health Effects Division (HED) Risk Assessment. Office of Prevention, Pesticides and Toxic Substances, United States Environmental Protection Agency, Washington, DC, USA.

- US FD&C Act, 1958. Federal Food, Drug, and Cosmetic Act, as amended Title 21 U.S. Code. US Governmental Printing Office, Washington, DC, USA.
- US FDA, 1995. Food additives: threshold of regulation of substances used in food contact articles: final rule. Fed. Regist. 60, 36582–36596.
- USDA, 2014. Pesticide Data Program: Annual Summary, Calendar Year 2013. US Department of Agriculture. https://www.ams.usda.gov/sites/default/files/media/ 2013%20PDP%20Anuual%20Summary.
- USDA, 2016. Pesticide Data Program: Annual Summary, Calendar Year 2014. US Department of Agriculture. https://www.ams.usda.gov/sites/default/files/media/ 2014%20PDP%20Annual%20Summary.pdf.
- Wang, Z., Scott, W.C., Williams, E.S., Ciarlo, M., DeLeo, P., Brooks, B.W., 2018. Identification of novel uncertainty factors and thresholds of toxicological concern for health hazard and risk assessment: application to cleaning product ingredients. Environ. Int. 113, 357–376.
- Williams, E.S., Berninger, J.P., Brooks, B.W., 2011. Application of chemical toxicity distributions to ecotoxicology data requirements under REACH. Environ. Toxicol. Chem. 30, 1943–1954.
- Xie, W., Han, C., Qian, Y., Ding, H., Chen, X., Xi, J., 2011. Determination of neonicotinoid pesticides residues in agricultural samples by solid-phase extraction combined with liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 1218, 4426–4433.
- Zhang, Q., Li, Z., Chang, C.H., Lou, J.L., Zhao, M.R., Lu, C., 2018. Potential human exposures to neonicotinoid insecticides: a review. Environ. Pollut. 236, 71–81.